Benzinga | Feb 2, 2021 08:01AM EST

Vivos Therapeutics Submits FDA 510(k) Application For The Vivos mmRNA Oral Appliance

HIGHLANDS RANCH, Colo., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos") (NASDAQ:VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (OSA), today announced that it has submitted a 510(k) Class II application to the U.S. Food and Drug Administration (FDA) for its mmRNA oral appliance(tm) with indications to treat mild-to-moderate OSA, sleep-disordered breathing and snoring in adults.